Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Affiliation country
Publication year range
1.
Brain Res Bull ; 88(5): 467-70, 2012 Aug 01.
Article in English | MEDLINE | ID: mdl-22542883

ABSTRACT

Docosahexaeonic acid (DHA) is the final compound in the omega-3 polyunsaturated fatty acids (PUFA) synthetic pathway and the most abundant PUFA found in the brain. DHA plays an essential role in the development of the brain, and the intakes in pregnancy and early life affect growth and cognitive performance later in childhood. Recently, it has been proposed that dietary intake of DHA could be a non-pharmacological interventional strategy for the treatment of seizures in humans. However, to date, the experimental approaches to study the antiepileptic effect of DHA have been exclusively restricted to rodent models during short-to-medium periods of treatment. The purpose of the present study was to test the chronic anticonvulsivant effects of DHA supplementation in zebrafish from the pre-spawning stage to aging, taking advantage of our recently described kainate-induced seizure model using this animal. To that end, two groups of adult female zebrafish were fed with standard or 200mg/kg DHA-enriched diets during 1 month previous to the spawning, and offspring subdivided in two categories, and subsequently fed with standard or DHA diets, generating 4 groups of animals that were aged until 20 months. Afterward, KA was intraperitoneally administered and epileptic score determined. All the DHA-enriched groups presented antiepileptic effects compared to the control group, showing that DHA presents an anticonvulsant potential. Among the studied groups, zebrafish fed with DHA from the pre-spawning stage to aging presented the best antiepileptic profile. These results show a neuroprotective benefit in zebrafish fed with DHA-enriched diet before birth and during the whole life.


Subject(s)
Aging/drug effects , Aging/physiology , Docosahexaenoic Acids/administration & dosage , Kainic Acid/toxicity , Seizures/prevention & control , Animals , Docosahexaenoic Acids/physiology , Embryo, Nonmammalian , Female , Kainic Acid/antagonists & inhibitors , Male , Seizures/chemically induced , Seizures/embryology , Zebrafish
2.
Nutrition ; 26(11-12): 1082-7, 2010.
Article in English | MEDLINE | ID: mdl-20018483

ABSTRACT

OBJECTIVE: Intestinal microbiota plays an important role in the prevention of certain diseases during the pediatric years. Thus, there is an increasing interest in the addition of probiotics to infant formulas. The aim of this study was to evaluate the safety of a follow-on formula with Lactobacillus salivarius CECT5713 in 6-mo-old children. METHODS: The antibiotic susceptibility of L. salivarius CECT5713 was analyzed by a dilution method. A double-blinded, randomized, placebo controlled study was performed. Children (n = 80) were distributed in two groups and consumed the formula supplemented or not with probiotics (2 × 10(6) colony-forming units [cfu]/g) during 6 mo. Fecal samples were collected at enrollment, at 3 mo, and at the end of trial. Clinical and anthropometric evaluations were performed. Depending on the variable, one-way or two-way repeated measures analysis of variance were used for the statistical analysis. RESULTS: The antibiotic susceptibility profile of the strain resulted as safe. No adverse effects associated with the consumption of the probiotic formula were reported. In addition, clinical parameters did not differ between groups. Consumption of the probiotic supplemented formula led to an increase in the fecal lactobacilli content (7.6 ± 0.2 versus 7.9 ± 0.1 log cfu/g, P < 0.05). Lactobacillus salivarius CECT5713 was detected in the feces of volunteers from the probiotic group. Probiotic consumption induced a significant increase in the fecal concentration of butyric acid at 6 mo. CONCLUSION: Thus, a follow-on formula with L. salivarius CECT5713 is safe and well tolerated in 6-mo-old infants.


Subject(s)
Food Microbiology , Infant Formula , Lactobacillus , Milk, Human/microbiology , Probiotics/administration & dosage , Anti-Bacterial Agents/pharmacology , Butyric Acid/analysis , Diarrhea, Infantile/epidemiology , Diarrhea, Infantile/prevention & control , Double-Blind Method , Feces/chemistry , Feces/microbiology , Female , Gastrointestinal Tract/physiology , Humans , Infant , Lactobacillus/drug effects , Lactobacillus/growth & development , Lactobacillus/isolation & purification , Male , Microbial Sensitivity Tests , Microbial Viability , Probiotics/adverse effects , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/prevention & control , Time Factors , Water/analysis
4.
Br J Nutr ; 98 Suppl 1: S96-100, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17922969

ABSTRACT

Breast milk is the best food for the neonate because it provides a unique combination of proteins, carbohydrates, lipids, minerals and vitamins that ensures the correct growth and development of the infant. In addition, it also contains bioactive compounds responsible for a wide range of beneficial effects such as the promotion of immune system maturation and the protection against infections. Among these bioactive agents, probiotic bacteria have been recently isolated from human milk. The present work reviews the beneficial effects of these bacteria both in animal models and in clinical trials. The promotion of immune system maturation and defence against infections as well as the anti-inflammatory properties are among the main healthy effects of these bacteria. The isolation of probiotic bacteria with beneficial effects for the host provides scientific support for the supplementation of infant formula with these bacteria, in order to advance the pursuit of the main goal of formula: to mimic breast milk and its functional effects as closely as possible.


Subject(s)
Lactobacillus/isolation & purification , Milk, Human/microbiology , Probiotics , Bacterial Infections/prevention & control , Breast Feeding , Female , Humans , Immune System/growth & development , Infant, Newborn , Intestines/immunology , Intestines/microbiology , Lactobacillus/classification , Virus Diseases/prevention & control
5.
Nutrition ; 23(3): 254-60, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17352961

ABSTRACT

OBJECTIVE: We studied the coadjuvant capability of oral consumption of the breast-milk-isolated strain Lactobacillus fermentum (CECT5716) for an anti-influenza vaccine. METHODS: A randomized, double-blinded, placebo-controlled human clinical trial including 50 volunteers (31 male and 19 female) was performed to address the immunologic effects of an intramuscular anti-influenza vaccine in adults (33.0 +/- 7.7 y old). Fifty percent of volunteers received an oral daily dose of methylcellulose (placebo) or probiotic bacteria (1 x 10(10) colony-forming units/d) 2 wk before vaccination and 2 wk after vaccination. RESULTS: Two weeks after vaccination there was an increase in the proportion of natural killer cells in the probiotic group but not in the placebo group. The vaccination induced an increase in T-helper type 1 cytokine concentrations and in T-helper and T-cytotoxic proportions in both groups; however, the probiotic group showed a significant higher induction in some of these parameters. Regarding the humoral effects, induction of antibody response in the placebo group could not be detected. In the case of the probiotic group, a significant increase in antigen specific immunoglobulin A was detected. Although an increase in total immunoglobulin M was observed, changes in anti-influenza antigen specific immunoglobulin M were not observed. The incidence of an influenza-like illness during 5 mo after vaccination (October to February) was lower in the group consuming the probiotic bacteria. CONCLUSION: Oral administration of the strain L. fermentum CECT5716 potentates the immunologic response of an anti-influenza vaccine and may provide enhanced systemic protection from infection by increasing the T-helper type 1 response and virus-neutralizing antibodies.


Subject(s)
Antibody Formation , Immunity, Cellular , Influenza Vaccines/immunology , Limosilactobacillus fermentum/immunology , Probiotics , Adjuvants, Immunologic/administration & dosage , Administration, Oral , Adult , Antibodies, Viral/biosynthesis , Dietary Supplements , Double-Blind Method , Female , Humans , Male , Probiotics/administration & dosage , Time Factors
6.
Lipids ; 41(12): 1115-25, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17269557

ABSTRACT

The higher incidence of inflammatory diseases in Western countries might be related, in part, to a high consumption of saturated fatty acids and n-6 polyunsaturated fatty acids (PUFA) and an insufficient intake of n-3 fatty acids. The purpose of this study was to examine the effects of dietary n-3 fatty acids on innate and specific immune response and their anti-inflammatory action in models of contact and atopic dermatitis. Balb/C mice were fed for 3 wk either n-6 or n-3 PUFA-fortified diets. After inducing a contact or an atopic dermatitis, immunological parameters were analyzed to evaluate the anti-inflammatory potential of these n-3 PUFA. n-3 PUFA reduced innate and specific immune responses through inhibition of TH1 and TH2 responses, increase of immunomodulatory cytokines such as IL-10, and regulation of gene expression. The inhibition of both kinds of responses was confirmed by the anti-inflammatory effect observed in contact and atopic dermatitis. Reduction in weight, edema, thickness, leukocyte infiltration, and enhancement of antioxidant defenses in the inflamed ears of mice from both models along with the prevention of delayed-type hypersensitivity induced in atopic dermatitis proved n-3 PUFA efficacy. Our data suggest that dietary fish oil-derived n-3 fatty acids have immunomodulatory effects and could be useful in inflammatory disorders.


Subject(s)
Cytokines/metabolism , Fatty Acids, Omega-3/pharmacology , Fish Oils/pharmacology , Inflammation/prevention & control , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/pharmacology , Cell Proliferation/drug effects , Cells, Cultured , Cytokines/genetics , Dermatitis/prevention & control , Eicosanoids/metabolism , Enzyme-Linked Immunosorbent Assay , Fatty Acids, Omega-3/administration & dosage , Fish Oils/administration & dosage , Gene Expression/drug effects , Lipids/blood , Lymphocytes/cytology , Lymphocytes/drug effects , Lymphocytes/metabolism , Macrophages/drug effects , Macrophages/metabolism , Male , Mice , Mice, Inbred BALB C , PPAR alpha/genetics , PPAR gamma/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction
7.
Eur J Nutr ; 44(8): 509-16, 2005 Dec.
Article in English | MEDLINE | ID: mdl-15719157

ABSTRACT

BACKGROUND: Polyunsaturated fatty acids play a key role in a number of biological functions. Rice bran oil (RBO) is rich in linoleic acid, an essential n-6 fatty acid. n-6 fatty acids are said to have proinflammatory effects as a result of an increase in n-6 fatty acid-derived eicosanoids. RBO is also rich in gamma-oryzanol, a compound from the unsaponifiable fraction, with antioxidant properties. OBJECTIVE: The aim of this work is to examine the effect of RBO-and/or gamma-oryzanol-enriched diets on the regulation of the immune response. METHODS: 4 week-old Balb/C mice were fed diets enriched with either RBO or high oleic-sunflower oil (HOSO), for one month. Serum samples, bone marrow-derived macrophages and lymphocytes from the spleen were collected. RESULTS: Compared to HOSO, our results show that RBO modulates the immune system by enhancing B-lymphocyte proliferation (6842 +/- 2959 vs 10073 +/- 4186 cpm; HOSO vs RBO; n = 10 per group) and TH1-type cytokines such as IL-2 (55.85 +/- 18.2 vs 101.7 +/- 21.6 pg/ml) or TNF-alpha (49.12 +/- 18.6 vs 184.9 +/- 46.2 pg/ml; HOSO vs RBO) in a significant way (n = 10 per group). Moreover, the reduction found in the TH2 cytokine IL-4 (7.59 +/- 2.3 vs 4.48 +/- 1.6 pg/ml) and IgE (56.9 +/- 39.2 vs 42.4 +/- 35.2 ng/ ml; HOSO vs RBO, n = 10 per group) levels suggests RBO may have antiallergenic properties. To elucidate the role of gamma-oryzanol, a similar study was also carried out including diets enriched with refined RBO or HOSO containing gamma-oryzanol (2 %). Our results suggest that although gamma-oryzanol may modulate the immune system, it is not responsible for the overall immunostimulation effect seen for RBO. CONCLUSIONS: RBO-enriched diets could be useful in situations where a potentiation of the immune response was required. The fatty acids composition, more than the unsaponifiable fraction, might be responsible for this effect.


Subject(s)
Diet , Immunity , Oryza/chemistry , Plant Oils/administration & dosage , Animals , B-Lymphocytes/immunology , Behavior, Animal , Cells, Cultured , Fatty Acids/administration & dosage , Lymphocyte Activation , Macrophages/immunology , Male , Mice , Mice, Inbred BALB C , Oleic Acid/administration & dosage , Phenylpropionates/administration & dosage , Sunflower Oil , Th1 Cells/immunology , Th2 Cells/immunology
SELECTION OF CITATIONS
SEARCH DETAIL